Certain Dermoscopic Structures Linked to Melanoma Detection
WEDNESDAY, Aug. 4, 2021 -- Certain dermoscopic structures associated with melanoma detection may have diagnostic importance, including shiny white structures, pseudopods, and blue-white veil, according to a systematic review and meta-analysis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2021 Category: Pharmaceuticals Source Type: news

New Long-term Melanoma Data'Clearly Favor' IPI/NIVO New Long-term Melanoma Data'Clearly Favor' IPI/NIVO
Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 3, 2021 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Aug. 2, 2021 -- (Healthcare Sales & Marketing Network) -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, inves... Biopharmaceuticals, Oncology, FDA Alkermes, nemvaleukin, mucosal melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2021 Category: Pharmaceuticals Source Type: news

Almost Every Doctor Recommends Sunscreen. So Why Don ’t We Know More About Its Safety?
Each year, as Memorial Day approaches, Holly Thaggard braces herself for the headlines. About how sunscreen may be damaging coral reefs. About the possible flammability of spray-on sunscreen. Headlines—as there were this year—about how sunscreen contains chemicals that could harm your health. “This has happened every single year for the last decade of my life,” says Thaggard, founder of Texas-based Supergoop, a sunscreen company that brands itself as reef-safe and free of hundreds of potentially problematic ingredients. This year, the is-sunscreen-dangerous news cycle started in May, when Valisure, ...
Source: TIME: Health - August 2, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Public Health Source Type: news

What's Next After Anti-PD-1 Therapy for Melanoma Fails? What's Next After Anti-PD-1 Therapy for Melanoma Fails?
Dr Jeffrey Weber describes two studies with encouraging results for patients with advanced melanoma that has not responded to anti-PD-1 and other immunotherapies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Eliminating RNA-binding protein improves survival in aggressive leukemia
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer ’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at theUCLA Jonsson Comprehensive Cancer Center.The research,published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 — especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.In these ML...
Source: UCLA Newsroom: Health Sciences - July 29, 2021 Category: Universities & Medical Training Source Type: news

ECU professor developing melanoma treatment nets $110K grant from NC Biotech
An ECU professor is assessing the commercial feasibility of the potential treatment for melanoma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 22, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Antibiotics may help to treat melanoma
Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. (Source: World Pharma News)
Source: World Pharma News - July 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Antibiotics may help to treat melanoma
(KU Leuven) Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

Recent Trend: Melanoma Mortality Declining Rapidly Recent Trend: Melanoma Mortality Declining Rapidly
The drop in death rates has occurred despite increased incidence rates for both men and women.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA ® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene
NEW BRUNSWICK, N.J., JULY 14, 2021 – Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level. Internal testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and follow the instructions set forth below.The only sunscreen products impacted are aerosol products, specifically: NEUTROGENA® Beach Defense® aerosol sunscreen, NEUTROGENA® Cool Dry Sport aerosol sunscreen,NEUTROGENA® Invisible Daily™ defense aerosol sunscre...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates NSCLC and Melanoma Lead Continuing Fall in US Cancer Death Rates
Cancer death rates in the US continue to decline overall for many common cancers in both men and women, especially non –small cell lung cancer (NSCLC) and melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Risk Factors for Melanoma by Anatomical Site Risk Factors for Melanoma by Anatomical Site
Differing risk factors for melanoma by anatomical site, as found in this study, suggest a dual pathway for its pathogenesis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Melanoma of the eye: Preclinical tests show path toward treatment
(University of Alabama at Birmingham) A preclinical study offers hope for treatment of uveal melanoma, a rare and deadly cancer of the eye. A small molecule inhibitor has been identified that dampens the potent drivers of this tumor. In mouse models, the inhibitor strongly limited primary disease in the eye and metastatic tumor dissemination to the liver, and animals survived longer, without overt side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

A new approach to metastatic melanoma discovered
(IMIM (Hospital del Mar Medical Research Institute)) Combining chemotherapy with a BRAF oncogene inhibitor proves effective at treating this disease. The study, published in the journal Oncogene, was led by researchers from the Hospital del Mar Medical Research Institute, Hospital del Mar and CIBERONC. This alternative paves the way towards a new approach for patients affected by this type of tumour, which has no cure in the most advanced stages or cases of relapse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2021 Category: International Medicine & Public Health Source Type: news

U.S. Cancer Mortality Rates Down From 2014 to 2018
THURSDAY, July 8, 2021 -- Cancer death rates in the United States continued to decline overall from 2014 to 2018, with declines accelerating for lung cancer and melanoma, according to a report published online July 8 in the Journal of the National... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2021 Category: Pharmaceuticals Source Type: news

Annual Report to the Nation: Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate
Overall incidence rates continue to increase in women, children and adolescents and young adults. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - July 8, 2021 Category: American Health Source Type: news

Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths
(American Cancer Society) Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 8, 2021 Category: International Medicine & Public Health Source Type: news

Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Melanoma registry results shine light on rare pediatric cancer
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 6, 2021 Category: Biology Source Type: news

The Big Number: Sunburn and the dangers of skin cancer
Overexposure to ultraviolet rays not only accelerates the aging of your skin but also increases your risk for skin cancer — including melanoma, the deadliest type. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 4, 2021 Category: Consumer Health News Authors: Linda Searing Source Type: news

Consumer Health: UV radiation and your skin
July is UV Safety Month, which makes this a good time to learn more about the harmful effects of ultraviolet, or UV, radiation from sunlight or tanning beds. Skin cancer is the most common type of cancer, according to the American Cancer Society. Skin cancer develops primarily on areas of sun-exposed skin, including the scalp, face, lips, ears, neck, chest, arms, hands and legs.  The three main types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 4, 2021 Category: Databases & Libraries Source Type: news

Shining a Light on Sunscreens: Using Sunscreen Every Day Could Reduce Your Risk of Skin Cancer
SATURDAY, July 3, 2021 -- Sunscreen isn't just for pool gatherings and beach outings: Using sunscreen every day could reduce your risk of skin cancer, experts say. Daily use of at least an SPF 15 sunscreen can lower your risk of melanoma—... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 3, 2021 Category: General Medicine Source Type: news

Shining a Light on Sunscreens
SATURDAY, July 3, 2021 -- Sunscreen isn't just for pool gatherings and beach outings: Using sunscreen every day could reduce your risk of skin cancer, experts say. Daily use of at least an SPF 15 sunscreen can lower your risk of melanoma — the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 3, 2021 Category: General Medicine Source Type: news

Science Saturday: Melanoma test to help some patients avoid surgical biopsy
More than 100,00 people in the U.S. are expected to be diagnosed with melanoma this year — double the number of cases compared to 30 years ago, according to the American Academy of Dermatology Association.  "Melanoma accounts for only about 2% of skin cancers, but it causes a majority of skin cancer deaths," says Alexander Meves, M.D., a Mayo Clinic dermatologist whose laboratory in Mayo Clinic's Center for Individualized Medicine works on cutting-edge methods to diagnose and treat melanoma.… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - July 3, 2021 Category: Research Source Type: news

Mayo Clinic Q and A: Bleeding moles and skin checks
DEAR MAYO CLINIC: I have a significant number of moles. While most do not bother me, I have at least one that bleeds from time to time. Should I see my doctor for a mole that bleeds? ANSWER: Moles are groups of pigment cells, and nearly everyone has them. Most moles are harmless, but it's possible for melanoma — a rare but serious skin cancer — to develop in or near a mole. Although it may not… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 2, 2021 Category: Databases & Libraries Source Type: news

NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma
ASCO studies validate dual LAG-3 and PD-1 inhibition in advanced melanoma, with good tolerability profiles, says Jeffrey Weber.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Looking at tumors through a new lens
(Institute for Systems Biology) Neoadjuvant immune checkpoint blockade is a promising treatment for melanoma and other cancer types, and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve the treatment efficacy, researchers are looking for vulnerabilities in surgically removed glioblastoma tissues, but this has been difficult due to the vast differences within the tumor and between patients. To address this challenge, ISB researchers and their collaborators developed a new way to study tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news

Cell-based immunotherapy shows promise against melanoma
(Washington University School of Medicine) Researchers at Washington University School of Medicine in St. Louis have shown in preclinical studies conducted in mice and human cells that a type of immunotherapy based on natural killer cells could be effective against solid tumors, starting with melanoma, a type of skin cancer that can be deadly if not caught early. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news

EORTC and Pierre Fabre partner to address treatment gap for stage 2 melanoma patients
(European Organisation for Research and Treatment of Cancer) European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, design and execution of a large Phase 3 study investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2021 Category: Cancer & Oncology Source Type: news

Doctor Empathy After'the Bottom Drops Out of Your World'Doctor Empathy After'the Bottom Drops Out of Your World '
A book about surviving stage IV melanoma highlights the importance of the patient-doctor relationship and, in particular, empathy – and the lack of it.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Leopard gecko skin tumors traced to cancer gene
(Howard Hughes Medical Institute) In a rare gecko color variety known as Lemon Frost, scientists have traced an unusual coloring and tendency to form tumors to a gene linked to human melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

Common moles could serve as players in battling melanoma and preventing its recurrence
(Massachusetts General Hospital) The road to an effective melanoma prevention and treatment could involve suppressing Tregs, immune cells that block the activity of CD4+ T cells in moles. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2021 Category: Cancer & Oncology Source Type: news

BioNTech announces first patient dosed in Phase 2 clinical trial of mRNA-based BNT111 in patients with advanced melanoma
BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the Company's therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. (Source: World Pharma News)
Source: World Pharma News - June 22, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

'Suffocating' cancer: A new headway in melanoma immunotherapy
(Luxembourg Institute of Health) Led by Dr. Bassam Janji, from the Luxembourg Institute of Health, the team used gene editing technologies to show how targeting HIF-1α could not only inhibit tumor growth, but also drive cytotoxic immune cells to the cancer tissue. This discovery provided a valuable new target to make resistant melanomas more vulnerable to available anti-cancer treatments. Their findings were recently published in the reputable Oncogene journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2021 Category: Cancer & Oncology Source Type: news

Success for a New Type of Checkpoint Inhibitor Success for a New Type of Checkpoint Inhibitor
Promising results in a study of>700 treatment-naive advanced melanoma patients.Medscape Blogs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2021 Category: Consumer Health News Tags: Hematology-Oncology Blog Source Type: news

ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a recently approved checkpoint inhibitor combination of treatment. ONCOS-102, a genetically modified oncolytic adenovirus, showed an overall survival rate of between 21.9 and 25 months in a randomized phase II clinical trial when combined with standard chemotherapy in a first-line setting. By comparison, patients in the trial receiving only standard chemotherapy had a median survival of just 13.5 months. The vaccine is the lead product of Targovax, a small Scandinavian bio...
Source: Asbestos and Mesothelioma News - June 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

' Check Your Assumptions at the Door,' Advises Outlier Patient'Check Your Assumptions at the Door,' Advises Outlier Patient
A young Black woman diagnosed with melanoma twice before she turned 30 describes how off-the-mark comments from healthcare providers and others led her to feel marginalized and silenced.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Health Benefits of Coffee
Drinking coffee has been linked to a reduced risk of all kinds of ailments, including Parkinson ’s disease, melanoma, prostate cancer, even suicide. (Source: NYT Health)
Source: NYT Health - June 14, 2021 Category: Consumer Health News Authors: Jane E. Brody Tags: Coffee Caffeine Sleep Content Type: Service Diabetes Anxiety and Stress Depression (Mental) Parkinson ' s Disease Pregnancy and Childbirth Antioxidants Heart Deaths (Fatalities) Pollan, Michael Willett, Walter C Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Drug commonly used as antidepressant helps fight cancer in mice
A class of drug called monoamine oxidase inhibitors is commonly prescribed to treat depression; the medications work by boosting levels of serotonin, the brain ’s “happiness hormone.”A new study by UCLA researchers suggests that those drugs, commonly known as MAOIs, might have another health benefit: helping the immune system attack cancer. Their findings are reported in two papers, which are published in the journals Science Immunology and Nature Communications.“MAOIs had not been linked to the immune system’s response to cancer before,” saidLili Yang, senior author of the study and a m...
Source: UCLA Newsroom: Health Sciences - June 10, 2021 Category: Universities & Medical Training Source Type: news

Cardinal Health(TM) Nuclear and Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK(R) Pediatric Indication
The new indication will provide accurate and precise lymph node identification in pediatric patients one month and older with melanoma, rhabdomyosarcoma or other types of solid tumors DUBLIN, Ohio, June 10, 2021 -- (Healthcare Sales & Marketing Network)... Biopharmaceuticals, Radiology, Oncology, FDA Cardinal Health, LYMPHOSEEK, sentinel lymph node biopsies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 10, 2021 Category: Pharmaceuticals Source Type: news

Barriers to Physician Skin Exam ID'd for Young Melanoma Survivors
WEDNESDAY, June 9, 2021 -- Barriers to health care access, especially cost, are associated with increased odds of not having an annual physician skin examination (PSE) among young melanoma survivors, according to a research letter published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2021 Category: Pharmaceuticals Source Type: news

The First Treatment for Alzheimer ’s Disease Is Here
Alzheimer’s disease was first described by Alois Alzheimer in 1906, and now, more than 100 years later, doctors have an effective drug to treat the cognitive disorder. On June 7, the U.S. Food and Drug Administration (FDA) approved aducanumab, developed by the U.S.-based biotech Biogen and Japanese pharmaceutical company Eisai. But the drug’s approval comes with a caveat. The FDA is requiring Biogen to conduct an additional placebo controlled study of the drug to verify it’s effectiveness in improving people’s memory and cognitive symptoms. That request stems in large part from the conclusion of an ...
Source: TIME: Health - June 7, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news

Analyzing tumor microenvironment at single cell level sheds light on metastatic melanoma outcomes
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers reveal how different therapies impact the surrounding immune environment of metastatic melanoma tumors according to location and identify a rare population of immune cells that is associated with improved overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma
(SWOG Cancer Research Network) Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

' Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma'Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma
For patients with advanced melanoma resistant to anti-PD-L1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent'should be favored'over ipilimumab alone as second-line immunotherapy, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news